Revisiting the Cuban Healthcare Sector

Revisiting the Cuban Healthcare Sector

The death of longtime Cuban leader Fidel Castro is a potential watershed event for the economic course of the island nation. Diplomatic détente between Cuba and the United States was already underway earlier this year when Kalorama Information provided an overview of Cuban biopharmaceuticals, medical devices, and medical care. Through a combination of economic and healthcare policies prioritized under the Castro regime and the unrelenting pressure of globalization, Cuba may soon emerge as a significant player in global healthcare industries.


Autoimmune Diagnostics: Analyst Q&A

Autoimmune Diagnostics: Analyst Q&A

What are the main trends in autoimmune testing? What growth rate is expected for revenues, and what are the main companies competing in this important in vitro diagnostic segment. What are the key future trends in AIIVD? We asked these questions of the analyst of Kalorama Information's most recent market research study: Automimmune IVD Testing Markets


Uncertain Consequences for U.S. Health Care Post-Election

Uncertain Consequences for U.S. Health Care Post-Election

Incoming Republican congressional majorities and an administration of president-elect Trump have injected plenty of uncertainty into the U.S. healthcare system. Dismantling the Affordable Care Act (ACA) will be a legislative priority of the new regime, but could take years to accomplish. Which ACA provisions are kept and how coverage is preserved for newly insured individuals are currently open questions.

  • by Bruce Carlson
  • November 11 2016
  • IVD


Siemens Healthineers: Divestment Makes Sense

Siemens Healthineers: Divestment Makes Sense

Healthcare companies should be healthcare companies. In the IVD market, Siemens is the No. 3 Company, according to Kalorama Information. Most of its competitors are healthcare-only companies, while Siemens Healthineers's parent is a conglomerate with many larger parts. Now the parent has announced it will divest the healthcare part of the business. We think it is logical.

  • by Bruce Carlson
  • November 9 2016


Second-Generation Wearables Hit the Marketplace

Second-Generation Wearables Hit the Marketplace

Wearable medical devices are performing advanced functions. Advances in wearable medical devices include new miniaturized sensors; peripherals; real-time measurements and interactions, wireless communication, sort and analyze features, portability and data transfer capabilities. To reach full potential, wearable medical technology has to cross the boundary from consumer electronic devices to regulated medical devices.


Moonshot Initiative Promotes Next Generation of Molecular Cancer Diagnostics

Moonshot Initiative Promotes Next Generation of Molecular Cancer Diagnostics

Cancer is the common thread through several fronts of U.S. regulatory development, whether approval of targeted therapeutics; coverage and reimbursement decisions for advanced diagnostic laboratory tests (ADLTs); or expansion of FDA regulatory oversight over laboratory developed tests (LDTs). The disease is also a healthcare and research and development (R&D) focus of the Obama administration. Just as instrumental as cancer’s high societal burden and aging-driven rise in incidence, the proliferation of its genetic analytes and druggable targets has caught the attention of regulators.